4. Integrated genetic risk assessment in De-novo Acute Myeloid Leukemia in children and young adults

In July, 2020, a new therapeutic trial for pediatric de-novo AML (AAML1831) opened for enrollment in Children's Oncology Group. The trial utilizes integrated cytogenetic, FISH, and DNA and RNA sequencing data for the purpose of risk stratification and determination of therapy. There are 17 genetic findings that are designated as high risk for which therapy includes hematopoietic stem cell transplant, and four genetic findings that are designated as low risk for which therapy includes chemotherapy only (in the absence of minimal residual disease) .

Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Betsy Hirsch, Todd Cooper, Jessica Pollard, Todd Alonzo, Soheil Meschinchi, Wendy Lee, Matthew Kutny, E. Anders Kolb, Gordana Raca Source Type: research